Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 0.42
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell